U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C25H35NO5
Molecular Weight 429.5501
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEBEVERINE

SMILES

CCN(CCCCOC(=O)c1ccc(c(c1)OC)OC)C(C)Cc2ccc(cc2)OC

InChI

InChIKey=VYVKHNNGDFVQGA-UHFFFAOYSA-N
InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021

Mebeverine is an antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract. The exact mechanism of action is not known, but multiple mechanisms, such as a decrease in ion channel permeabilities, blockade of noradrenaline reuptake, a local anesthetic effects, as well as weak anti-muscarinic and phosphodiesterase inhibitory effect might contribute to the local effects of Mebeverine. This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Most people will not have problems with Mebeverine, but some may get some side effects, such as: difficulty in breathing, swelling of face, neck, tongue or throat, skin rash, red itchy skin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Alpha-1 adrenergic receptor (guinea pig)
Target ID: Muscarinic acetylcholine receptors (guinea pig)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Colofac

Approved Use

Colofac is used to treat symptoms of irritable bowel syndrome and similar problems.

Launch Date

2.58595193E11
Palliative
Colofac

Approved Use

This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis.

Launch Date

2.58595193E11
Palliative
Colofac

Approved Use

This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis

Launch Date

2.58595193E11
PubMed

PubMed

TitleDatePubMed
The antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassay (FPIA)--studies on the toxicological analysis of urine by FPIA and GC-MS.
2001 Jul-Aug
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome.
2001 Mar
A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine.
2002 Nov
On-line micellar electrokinetic chromatography-mass spectrometry: feasibility of direct introduction of non-volatile buffer and surfactant into the electrospray interface.
2003 Jun 6
Spectrophotometric microdetermination of nefopam, mebevrine and phenylpropanolamine hydrochloride in pharmaceutical formulations using alizarins.
2004 Jul
[Abdominal migraine as a cause of chronic recurrent abdominal pain in a 9-years-old girl--case report].
2005 Aug
Simultaneous determination of mebeverine hydrochloride and sulpiride using the first derivatives of ratio spectra and chemometric methods.
2005 Aug
Atmospheric pressure photoionization for enhanced compatibility in on-line micellar electrokinetic chromatography-mass spectrometry.
2005 Aug 15
Potentiometric flow injection analysis of mebeverine hydrochloride in serum and urine.
2005 Jan 4
[Mebeverine for complex treatment of opisthorchiasis].
2006
A validated chiral HPLC method for the determination of mebeverine HCl enantiomers in pharmaceutical dosage forms and spiked rat plasma.
2006 Feb
"My patients are the sickest".
2006 May
[Assessment of the efficacy of mebeverine in the complex therapy of chronic noncalculolis cholecystitis and biliary dysfunction].
2007
Development of in situ ion selective sensors for dissolution.
2007 Jan 2
[Drug treatment of irritable bowel syndrome: an unmet need].
2007 Mar
[Efficacy of duspatalin in the treatment and prophylaxis of postcholecystectomic syndrome].
2008
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.
2008 Nov 13
Drug use in children: cohort study in three European countries.
2008 Nov 24
[The effectiveness of spasmolytic therapy in chronic acalculous cholecystitis].
2009
Psychological associations of irritable bowel syndrome besides panic disorder: an often overlooked reality.
2009
pH-Sensitive Mebeverine Microspheres for Colon Delivery.
2009 Jul
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
First derivative synchronous fluorescence spectroscopy for the simultaneous determination of sulpiride and mebeverine hydrochloride in their combined tablets and application to real human plasma.
2010 Nov
Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial).
2010 Nov 18
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Sample Use Guides

One tablet (135 mg) three times a day. This may be gradually reduced after a few weeks when the desired effect has been obtained. The tablets are best taken 20 minutes before meals.
Route of Administration: Oral
In Vitro Use Guide
Mebeverine (10^5-10^4 M) suppressed the amplitude of the action potential and lengthened the time between stimulation and the top of the response in non-myelinated fibres of the vagus nerve.
Name Type Language
MEBEVERINE
INN   MI   WHO-DD  
INN  
Official Name English
MEBEVERINE [MI]
Common Name English
MEBEVERINE [WHO-DD]
Common Name English
ARLUY
Brand Name English
BENZOIC ACID, 3,4-DIMETHOXY-, 4-(ETHYL(2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)BUTYL ESTER
Common Name English
VERATRIC ACID, 4-((ETHYL(P-METHOXY-.ALPHA.-METHYLPHENETHYL))AMINO)BUTYL ESTER
Common Name English
4-(ETHYL(P-METHOXY-.ALPHA.-METHYLPHENETHYL)AMINO)BUTYL VERATRATE
Common Name English
MEBEVERINE [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66880
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
WHO-ATC A03AA04
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
WHO-VATC QA03AA04
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
Code System Code Type Description
EPA CompTox
3625-06-7
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
FDA UNII
7F80CC3NNV
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
DRUG CENTRAL
1642
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
CAS
3625-06-7
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
RXCUI
29410
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY RxNorm
PUBCHEM
4031
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
ECHA (EC/EINECS)
222-830-4
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
ChEMBL
CHEMBL282121
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
EVMPD
SUB08662MIG
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
MERCK INDEX
M7108
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY Merck Index
MESH
C005096
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
WIKIPEDIA
MEBEVERINE
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
INN
1191
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
DRUG BANK
DB12554
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY
NCI_THESAURUS
C83909
Created by admin on Sat Jun 26 01:12:23 UTC 2021 , Edited by admin on Sat Jun 26 01:12:23 UTC 2021
PRIMARY